USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
30 Jul 2024
Historique:
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: ppublish

Résumé

Androgen receptor (AR) is a main driver for castration-resistant prostate cancer (CRPC). c-Myc is an oncogene underlying prostate tumorigenesis. Here, we find that the deubiquitinase USP11 targets both AR and c-Myc in prostate cancer (PCa). USP11 expression was up-regulated in metastatic PCa and CRPC. USP11 knockdown (KD) significantly inhibited PCa cell growth. Our RNA-seq studies revealed AR and c-Myc as the top transcription factors altered after USP11 KD. ChIP-seq analysis showed that either USP11 KD or replacement of endogenous USP11 with a catalytic-inactive USP11 mutant significantly decreased chromatin binding by AR and c-Myc. We find that USP11 employs two mechanisms to up-regulate AR and c-Myc levels: namely, deubiquitination of AR and c-Myc proteins to increase their stability and deubiquitination of H2A-K119Ub, a repressive histone mark, on promoters of AR and c-Myc genes to increase their transcription. AR and c-Myc reexpression in USP11-KD PCa cells partly rescued cell growth defects. Thus, our studies reveal a tumor-promoting role for USP11 in aggressive PCa through upregulation of AR and c-Myc activities and support USP11 as a potential target against PCa.

Identifiants

pubmed: 39052835
doi: 10.1073/pnas.2403331121
doi:

Substances chimiques

AR protein, human 0
Histones 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
Receptors, Androgen 0
Thiolester Hydrolases EC 3.1.2.-
USP11 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2403331121

Subventions

Organisme : HHS | NIH | National Cancer Institute (NCI)
ID : R01CA244667
Organisme : U.S. Department of Defense (DOD)
ID : PC210437

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Majid Pornour (M)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201.

Hee-Young Jeon (HY)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201.

Hyunju Ryu (H)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201.

Sudeep Khadka (S)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201.

Rui Xu (R)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Department of Marine Biotechnology, Institute of Marine and Environmental Technology, University of Maryland, Baltimore, MD 21202.

Hegang Chen (H)

Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD 21201.

Arif Hussain (A)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201.
Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201.

Hung-Ming Lam (HM)

Department of Urology, University of Washington, Seattle, WA 98195.

Zhihao Zhuang (Z)

Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716.

Htoo Zarni Oo (HZ)

Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.

Martin Gleave (M)

Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.

Xuesen Dong (X)

Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.

Qianben Wang (Q)

Department of Pathology and Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710.

Christopher Barbieri (C)

Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY 10065.

Jianfei Qi (J)

Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD 21201.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH